Cytek Biosciences Inc (CTKB) — Cash Flow Reinvestment Rate
Cytek Biosciences Inc (CTKB) has a Cash Flow Reinvestment Rate of 166.57x as of June 2025, reinvesting $17.99 Million (capex $1.58 Million plus investments $-16.41 Million) from operating cash flow of $108.00K. Check Cytek Biosciences Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cytek Biosciences Inc Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for Cytek Biosciences Inc across 4 annual periods. Explore Cytek Biosciences Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Cytek Biosciences Inc (2020–2024)
Year-by-year capital reinvestment analysis for Cytek Biosciences Inc. For live market cap and broader valuation context, see CTKB stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.41x | $86.50 Million | $25.38 Million | $3.52 Million | ▼ -89.9% |
| 2023 | 33.87x | $178.85 Million | $5.28 Million | $4.83 Million | ▲ +518.4% |
| 2021 | 5.48x | $25.36 Million | $4.63 Million | $4.36 Million | ▲ +2582.8% |
| 2020 | 0.20x | $3.09 Million | $15.16 Million | $1.55 Million | — |